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INTRODUCTION 
 
 
Tuberculosis is a curable infectious disease causing significant morbidity and preventable  
 
deaths  worldwide. This  disease  usually affects  the  Lungs , although  other  organs  are  
 
involved in up to one-third of cases. 
 
 
India  , China  , Indonesia  ,  South Africa   and    Nigeria  rank  first  to  fifth    Countries 
 
respectively in terms of absolute number of cases. 
 
 
By recent survey in India both  pulmonary and  extra-pulmonary TB cases are endemic in 
 
Indian  subcontinent .  India  has  the highest TB  burden in the world in terms of absolute 
 
number  of  incident  Cases .  To  make  the  situation  worse , TB  has  formed   a    lethal 
 
partnership  with  HIV.Untreated  HIV  infection is the greatest risk factor for progression 
 
from  Latent  Tuberculosis  infection  to  TB  disease . Hence   timely   screening   for  TB   
 
infection  and   treatment in HIV-infected  people  is   necessary  to  increase  the  chances  
 
of  survival  and  reduce the transmission of TB in the community. 
 
 
In India  broad- spectrum  antibiotics  are  being  prescribed  inappropriately leading on to 
 
MDR-TB.  Studies  have  reported  that  MDR-TB is significantly higher among treatment  
 
failures.This can be prevented by early referral  for  culture. Nowadays, Radiometry using  
 
BACTEC instrument is used to reduce the diagnostic time in cultured specimens. But still,  
 
using  this  technique,  organisms  can be detected only after 7 to 8 days in  smear positive  
 
patients and 16 to20 days in smear negative patients1. 
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While the treatment of TB is considered one of the most cost-effective interventions in 
 
DOTS  programme, we are still without a fast and simple diagnostic test that would be 
 
applicable in high-burden but resource-poor settings. 
 
 
The present study was conducted to find an application of serum  Ferroxidase/albumin 
 
ratio  as a  marker to assist in diagnosis and monitoring the prognosis of  PTB patients. 
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AIM AND OBJECTIVE 
 
 
The aim of this study is to incorporate Serum Ferroxidase/albumin ratio as    
 
a surrogate  marker  to assist  in  diagnosis  and  prognosis  of   Pulmonary 
 
tuberculosis patients. 
 
 
The Objective of this study- 
 
 
•  To  measure  and document the serum Ferroxidase/ albumin ratio in 
 
      freshly diagnosed and completely treated cases with PTB. 
 
       
• To  compare  the  serum  ferroxidase /albumin  ratio between freshly  
 
     diagnosed cases of PTB and apparently healthy controls. 
 
       
• To compare the serum ferroxidase/ albumin ratio between completely  
 
treated cases of PTB and apparently healthy controls. 
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REVIEW OF LITERATURE 
 
 
Once  thought  to  be  under  control ,  TB  is  now  the number one cause of  
 
infection  related  death  world-wide2. One  third of  the global population is  
 
infected with TB, of which 95% of the incidence is in developing countries3.  
 
At  present ,  ~2  billion  people  are  infected  with  TB  and  the  number is  
 
expected to increase by 20204. WHO estimated that 1.5 million people  died 
 
from TB in 20065. 
                
 
The  resurgence  of  TB  due  to  rise in drug-resistant strains made WHO to  
 
declare TB as global health emergency in 19936. 
 
 
WHO-THE GLOBAL PLAN TO STOP TB 2006-2015 
 
 
Achievement of the millennium development goal:" to have  halted  by 2015   
 
and begun to reverse the incidence "of TB7. 
 
 
EPIDEMIOLOGY 
 
 
According to US center for disease control and prevention, 
 
Clinical case definition8 
 
A case that meets all of the following criteria: 
 
*A positive tuberculin skin test  
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*Other signs and symptoms compatible with TB, such as abnormal chest  
 
  radiograph or clinical evidence of current disease. 
 
 
*Treatment with two or more ant tuberculosis medications 
 
 
  Laboratory criteria for diagnosis8 
 
 
*Isolation of MTB from a clinical specimen. 
 
 
*Demonstration of MTB from a clinical specimen by NAA test (Nucleic  
 
 Acid Amplification Test ) 
    
 
*Demonstration  of  AFB  in   a clinical specimen when a culture has not  
 
  been or cannot be obtained.       
                 
 
  It  is  this last definition  that  satisfies the  only  criteria  available  in  a  
 
  resource-poor setting where only microscopy is available. 
   
 
  EPIDEMIOLOGICAL INDICES IN INDIA (2006)10 
 
 
  Population (thousands)                                                              :1 151 751 
 
  Global rank (based on incident cases)                                       :Rank1 
            
  Incidence (all cases/100 000 population/year)                          :168           
 
  Incidence (sputum smear positive/100 000 pop/yr)                  :75 
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Prevalence (all cases /100 000 pop)                                                      : 299 
 
Mortality (deaths/100 000 pop/yr)                                                        : 28 
 
               *of new TB cases, % HIV positive                                        : 1.2 
 
               *of new TB cases, % MDR-TB                                             : 2.8 
          
    
INTERESTING FACTS ABOUT TB 
 
 
TB has been present in humans since ancient times. The earliest detection  
 
of MTB is in the remains of bison dated 17,000 years before the present11. 
 
Skeletal remains show prehistoric humans (3500-2650 BC) had TB12  and  
 
tubercular decay has been found in the spines of mummies13, 14. 
 
 
OTHER NAMES OF TB 
 
 
It  includes  Phthisis  ( Greek for consumption ) ; wasting  disease  ;  white    
 
plague because sufferers appear markedly pale ; King’s evil because it  was  
 
believed that a King’s  touch  would  heal the disease; Koch’s disease, after    
 
the discovery of TB by Robert Koch15. 
 
 
WORLD TB DAY  
 
 
It  falls  on  24  March  each  year. It is designed to build public awareness  
 
about TB16.   
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ETIOLOGY OF TB 
 
 
Mycobacterium  belong  to  the  family  mycobacteriacea  and  the order  
 
actinomycetales.  MTB  is  the  most  common  and  important agent  of  
 
human disease.  MTB,  which is  a rod-shaped, aerobic bacterium resists  
 
decolorization by acid alcohol on  gram’s staining. Hence called as Acid- 
 
fast bacilli17. 
 
 
CELL WALL OF MTB 
 
 
High content of  mycolic  acid and  long  chain  cross- linked  fatty acids,      
 
mono  and  multiacylated   trehalose  glycolipids,  diacylated  long-chain  
 
polyketol  diols and acylated  phosphatidyl – myo - inositol- mannosides  
 
present in the  cell wall of  MTB  contributes acid-fastness to the bacilli18. 
 
 
HOST FACTORS 
 
 
1 .Age: TB affects all ages19. 
 
2. Sex: TB is more prevalent in males than in females20. 
 
3. Nutrition:  Malnutrition  is  important risk factor for acquiring TB21. 
 
 
SOCIAL FACTORS 
 
 
Poor quality of life, homelessness22, lack of  education, lack of  awareness   
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of TB, tobacco smoking23 are some of the known social factors contributing to  
 
the risk of TB infection. 
 
 
MODE OF TRANSMISSION 
 
 
MTB from infectious PTB patients spread to others by droplet nuclei,  which  
 
are aerosolized by coughing, sneezing or speaking. 
 
 
RISK FACTORS FOR DEVELOPING ACTIVE TB 
 
 
1.Risk of active TB  in adult-house  hold  contacts  of  smear positive  PTB is  
 
   high24. 
 
 
2.Risk of active TB  among  persons  who   have  been  infected with tubercle  
 
   bacilli includes- 
 
                 * Recent infection (<1 yr) 
 
                 * Fibrotic lesions 
 
                 * Comorbidity-HIVinfection 
 
                 * Silicosis 
 
                 * Chronic renal failure 
 
                 * Diabetes 
 
                 * Intravenous drug use 
 
                 * Immunosuppressive treatement25 
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CLINICAL MANIFESTATIONS OF PTB 
 
 
It  includes   
 
1. Chest pain,  
 
2. Coughing up blood, and 
 
3. A productive, prolonged cough for more than 3 weeks.  
 
 
Systemic symptoms includes 
 
1. Fever,  
 
2. Chills,  
 
3. Night sweats,  
 
4. Appetite loss,  
 
5. Weight loss,  
 
6. Pallor, and  
 
7. Easy fatigability.  
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PATHOGENEGIS OF  PTB 
 
 
PTB  infection  begins  with  inhalation of  mycobacterium from infectious  
 
patients. Inhaled bacilli  reaches  the alveoli. There, alveolar  macrophages  
 
phagocytize  the  bacilli and the phagocytosis is  enhanced by complement  
 
activation26.  After a  phagosome forms, the  survival  of MTB depends on  
 
virulence of tubercle bacilli. 
 
 
VIRULENCE OF TUBERCLE BACILLI 
 
 
Lipo-  arabinomannan,  a glycolipid  in  the  bacterial  cell wall inhibits the     
 
intra - cellular  increase  of  calcium.  This  impairs   calcium / calmodulin  
 
dependent  fusion  of  phagosome  –  lysosome  thereby  it   facilitates   the      
 
survival of bacilli within the  phagosome27. 
 
 
IMMUNOLOGIC RESPONSE TO MTB 
 
 
Once MTB antigens, such as early secretory antigenic target6-KDa (ESAT- 
 
6) are  internalized28,  the  macrophages digest them  into smaller fragments.  
 
These fragments(epitopes) binds to infected macrophages and other antigen  
 
presenting  cells  like monocytes  and  dendritric cells. Toll – like receptors  
 
(TLRs) play  an  essential  role  in  the   recognition  of  MTB fragments by  
 
macrophages and dendritic cells. This in turn  transports the epitopes  to the  
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macrophage surface for presentation to T lymphocytes29, 30.  
 
 
The result is the activation and proliferation of CD4+ T lymphocytes which  
 
contribute to  host  defense  by  macrophage-activating  response and tissue- 
 
damaging response31. 
 
 
MACROPHAGE-ACTIVATING RESPONSE 
 
 
Activated  CD4+ T cells  produce  cytokines  such  as IFN-γ,an activator of  
 
Macrophages  and  monocytes,  IL-2,  IL-5,  IL-10,  IL-13, IL-1 and TNF-α.  
 
These  cytokines  induce  the  generation  of reactive nitrogen intermediates  
 
which  has  anti mycobacterium activity. In addition, macrophages undergo  
 
apoptosis in containing the growth of the bacilli32, 33. 
 
 
TISSUE DAMAGING RESPONSE 
 
 
It is a delayed-type hypersensitivity  reaction  to various bacillary antigens. It  
 
destroys inactivated macrophages that contain bacilli but also causes caseous  
 
necrosis in the central part of lesion34. 
 
 
Although both these responses can  inhibit  mycobacterium growth,  it  is the  
 
balance  between  the  two  that  determines the form of TB that will develop  
 
subsequently35.  
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PATHOLOGICAL CLASSIFICATION OF PTB36 
 
 
PRIMARY TB 
 
 
It occurs soon after the initial infection with tubercle bacilli accompanied    
 
by  hilar or paratracheal lymphadenopathy. In  majority , the  lesion  heal  
 
spontaneously evident as Gohn’s lesion. 
               
 
At  the site of  primary lesion, the activated macrophages secrete various  
 
cytokines  resulting  in  the  formation  of  granuloma. Mycobacteria  are  
 
contained  within  granuloma and thus prevented from spreading all over      
 
the body. 
 
 
 
PROGRESSIVE PRIMARY TB36 
 
 
In  children  and  in  persons  with  impaired  immunity  (eg,  those  with  
 
malnutrition  or  HIV  infection ),  primary PTB may progress rapidly to  
 
clinical  illness. The  primary  site  rapidly  enlarges ,  its central portion  
 
undergoes necrosis and cavitation. 
 
 
 
POST PRIMARY TB36 
 
 
Also  called  adult-type  or  secondary TB,  post primary TB results from  
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endogenous  reactivation of latent infection. The characteristic pathological  
 
feature is the tuberculous cavity. 
                             
 
Granulomas of secondary TB fail to contain the spread of the TB infection  
 
and is the major cause of tissue damage in TB. 
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CERULOPLASMIN 
 
 
Cp  is  an  α 2 –globulin  that   contains  ~95% of the total copper  found  in  
 
serum37.Each  molecule  of Cp contains six to eight  copper atoms, most  of  
 
which are tightly bound. 
 
 
BIOCHEMISTRY 
 
 
Cp  has  a  single  polypeptide  chain  with   1046  amino acids   and    three  
 
Glucosamine - linked  oligosaccharide. The peptide chain  and carbohydrate  
 
together result in a mean molecular mass of 132 KDa.Cp is  very susceptible  
 
to   proteolysis  by  many  proteases   including  trypsin, plasmin,  leukocyte  
 
elastase, and a plasma metalloproteinase38. 
 
 
SITE OF SYNTHESIS 
 
 
Cp is synthesized  primarily  by  the  hepatic parenchymal cells, with  small  
 
amounts synthesized by macrophages and lymphocytes. 
                          
 
Recent  studies have identified the lung as another site  of Cp synthesis  and  
 
support   Cp critical  role  in  host  defense  against  oxidative  damage   and  
 
infection in the lung39. 
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CLINICAL SIGNIFICANCE40, 41 
 
 
Increased plasma levels 
 
 
1. Primary (Genetic) elevation.   
 
2. Secondary elevation : Synthesis  of  Cp is  increased in acute phase  
 
     reaction.  Synthesis  is  stimulated  markedly  by   oestrogen.Larger  
 
     increase occurs during pregnancy. 
 
 
Decreased plasma levels 
 
 
      1.   Primary (Genetic) deficiency. 
 
      2.   Secondary   deficiency   due   to   dietary   Copper    insufficiency        
 
            (including malabsorption), Menke’s, Wilson’s disease.    
 
            
FUNCTIONS OF Cp 
  
 
      1.   Cp  is  an  important  extracellular   antioxidant   and  free  radical  
 
            scavenger42. 
 
 
      2.   Cp  is  a  plasma  protein  that  functions  as  a copper transporter43. 
 
 
 3.   Studies  in  atherosclerosis  have  reported   that   Cp   oxidatively  
 
            modifies Low Density Lipoprotein.The pro-oxidant activity of Cp  
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requires  an intact structure, and a single  copper atom at   the surface of the  
 
protein, near His 426 is required for LDL oxidation44. 
 
 
ROLE OF Cp DURING INFLAMMATION 
 
 
Elevation of serum Cp level during inflammation is one of the body’s inbuilt  
 
defensive mechanism45. 
 
                                     
During early  phase of inflammation  there is  increased  polymorphonuclear  
 
leukocyte (PMN) adhesion  to  the  endothelial  cells of the blood vessels for  
 
subsequent PMN migration between the endothelial cells into the connective  
 
tissue and  towards  the focus of injury. The adhesion event is influenced  by  
 
inflammatory  mediators, such  as  Leucotriene -B4 and  IL-1.Cp reduces the  
 
adhesion and  scavenges superoxide during the interaction of activated PMN  
 
leukocytes with endothelial cells46. 
 
 
Ferroxidase activity of Cp 
 
 
Acting  as  a  ferroxidase, Cp is vitally important in catalyzing the  enzymatic  
 
oxidation of ferrous iron to ferric iron47. This ferroxidase activity is important  
 
for  iron  fluxing  in  and  out  of  cells  because  iron  is  stored  in  its storage  
 
molecule (ferritin) and  transported  in  the blood in  the ferric form, bound to  
 
transferrin48. 
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Cp thus permits incorporation of ferric iron into transferrin. It prevents the  
 
formation of toxic iron products by inhibiting the fenton reaction. 
 
 
The Battle for Iron between MTB and its host 
 
 
MTB relies primarily on Iron chelating compounds called Siderophores for  
 
acquisition of iron from its  human host. Siderophores chelate  extracellular  
 
Fe3+ to form Fe3+ -Siderophore  complexes  that are captured by the bacteria  
 
for subsequent metabolism49. 
 
 
Cp by its ferroxidase  activity  oxidizes  ferrous iron,  facilitates its binding  
 
with transferrin and thereby inhibits the iron uptake by MTB. 
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STRUCTURE OF CERULOPLASMIN 
 
 
 
                     
 
 
 
 
 
 
                        REPRODUCED FROM WEBSITE:http://en.wikipedia.org/wiki/Ceruloplasmin 
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IRON 
 
 
Body Iron is distributed in different compartments including Hemoglobin,  
 
storage iron and Myoglobin. 
 
 
CLINICAL SIGNIFICANCE50 
 
 
Iron  deficiency  and   Iron  overload  are  the  major  disorders   of   Iron  
 
metabolism. 
 
 
REFERENCE VALUE: Male: 60 to 150 μg/dl, Female: 50 to 130 μg/dl 
 
 
COPPER 
 
 
Copper  is an  important trace element.90% of copper exported from liver   
 
into peripheral blood is in the form of ceruloplasmin. 
 
 
CLINICAL SIGNIFICANCE 
 
 
Copper  deficiency:  Seen  in   malnourished  infants ,  premature  infants,  
 
Menke’s syndrome .51 
 
 
Copper toxicity: Seen in Wilson’s disease51. 
 
 
REFERENCE VALUE:70 to 150 μg/dl 
 
 
 
20
ALBUMIN 
 
 
Albumin  is  the  most  abundant  plasma  protein  with   molecular  mass      
 
of 663KDa52. 
 
 
BIOCHEMISTRY 
 
 
Albumin  has  a  single  polypeptide  chain  of   580  amino acids with  no  
 
carbohydrate  side  chains52. It  is  a  very stable   protein with a  high  net  
 
negative  charge  at  physiological  pH. The   plasma half-life is   15 to 19  
 
days. 
 
 
SITE OF SYNTHESIS 
 
 
Albumin is synthesized primarily by the hepatic parenchymal cells except 
 
in early fetal life, when it is synthesized largely by the yolk sac. 
 
 
CLINICAL SIGNIFICANCE 
 
 
Relative increase in plasma levels 
 
It is seen in acute dehydration.Chronic Vomiting and diarrhea may impair  
 
intestinal   absorption  of  amino acids ,  so   reducing    plasma    albumin  
 
formation53. 
 
 
 
 
21
Decreased plasma levels: Occurs with 
       
 
    (1) An  impairment  in  synthesis ,  as  in  malnutrition  or  liver  disease  
 
    (2) An increase in catabolism, as in the acute phase reaction, 
 
    (3) Loss of protein through urine or faeces or 
 
    (4) Change in  distribution between  the  intravascular and  extra vascular  
 
          compartments54. 
 
 
 
FUNCTIONS54 
 
 
 
1. The primary function of albumin is maintenance of colloidal osmotic  
 
     pressure in both the vascular and extra vascular spaces. 
 
 
2. Albumin binds and transport a large number of compounds  including  
 
     free fatty acids, phospholipids, cholesterol, metallic ions, amino acids,  
 
     drugs, hormones, and bilirubin, among many others. 
 
       
3. Albumin  binds  many  hormones  such as Triiodothyronine or T3, but  
 
     with lower affinity. 
 
 
4. Albumin also  functions as an amino acid source for  peripheral tissue. 
 
 
5. Albumin is  an  important  component  of  plasma antioxidant activity. 
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6. Albumin  acts as a buffer, especially  in non physiological conditions. 
 
 
7. Albumin inhibits leukotriene and actin  production, thus reducing the  
 
     inflammatory response of platelets and neutrophils. 
 
 
8. Albumin  binds  copper  and transports it to the liver where copper  is  
 
     incorporated into cuproenzymes. 
 
 
ROLE OF ALBUMIN DURING INFLAMMATION54 
 
 
          Albumin level is decreased during inflammation because of following  
 
          factors. 
 
 
(1) Hemodilution. 
 
 
(2) Loss  into  the  extra  vascular  space  caused  by   increased  vascular  
 
     permeability. 
 
 
(3) Increased consumption by cells locally. 
 
 
(4) Decreased  synthesis  as  the  result  of  direct  inhibition by cytokines  
 
      
     (5) Increased  colloidal  osmotic  pressure (COP).  
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                                STRUCTURE OF ALBUMIN 
 
 
 
 
 
                          
 
                                          
 
 
 
 
 
               REPRODUCED FROM WEBSITE:http://en.wikipedia.org/wiki/Albumin 
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ACUTE PHASE RESPONSE 
 
 
It is a  non specific response  induced by bacterial infection. After infection  
 
with MTB, alveolar macrophages, neutrophils and granulocytes secrete pro- 
 
inflammatory cytokines, such as TNF-α  and IL-1 (IL-1α or IL-1β)  into the  
 
blood  stream. The liver  responds  to  these cytokines release by producing  
 
acute phase proteins55. 
 
 
MAJOR ASPECTS OF THE ACUTE PHASE RESPONSE56 
 
 
Metabolic aspects 
 
 
1. Protein catabolism. 
 
Inflammatory cytokines induces muscle protein  degradation and thereby  
 
provides amino acids for acute phase protein synthesis. 
 
 
2. Osteoporosis. 
 
 Increased resorption of bone occurs due to increase in pro inflammatory  
 
 cytokines levels. 
 
 
3. Increased hepatic lipogenesis. 
 
 Cytokines increases the synthesis of fatty acids. Tubercle bacilli inhibits   
 
 the  Lipoprotein  lipase  leading  to  decrease  in  clearance  of  very low  
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density  lipoprotein. 
 
 
Neuroendocrine changes 
 
 
1.Fever. 
 
2.Somnolence. 
 
3.Increased Corticotrophin-releasing hormone , Corticotrophin , and Cortisol. 
 
 
Cytokines stimulates hypothalamic, pituitary and  adrenal glands. Cytokines  
 
induce the production of corticotrophin-releasing factor. It generates Adreno  
 
corticotrophin  hormone  in  the  pituitary  and  then in turn corticosteroid in  
 
adrenal cortex. 
 
 
4.Increased  secretion  of  catecholamine’s  due  to  stimulation by cytokines. 
 
5.Decreased insulin-like growth factor 1(ILGF-1). 
 
 
Immunostimulatory  hormones  such  as  Growth  hormone  and  ILGF-1 are  
 
suppressed.  The  decrease in  concentration of growth hormone and ILGF-1  
 
are  the  reason  for the protein imbalance that leads to catabolism of muscle  
 
protein. 
 
 
Micronutrient changes 
 
 
1.Reduced serum Zinc  due to  increased  production  of  metallothionein  in 
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   liver. 
 
2.Reduced plasma Vitamin A because of  reduced  levels of carrier protein. 
 
 
Positive  acute  phase  proteins57  are  those  whose  plasma  concentration  
 
increase  during  inflammation.  Examples  are  – α1 Antitrypsin, α1  -   Anti  
 
chymotrypsin, Fibrinogen, Prothrombin, Factor VIII,Complement proteins,  
 
transport proteins such as Cp, Haemopexin,and Haptoglobin. 
 
 
Negative acute phase proteins57 are those plasma concentrations decreases  
 
during inflammation. Examples  are  Albumin,  Transthyretin, Transferrin,  
 
Retinol binding protein. 
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ACUTE PHASE REACTION 
 
 
 
 
       
 
 
 
 
 
REPRODUCED FROM WEBSITE:http://wiki.healthhaven.com/Acute-phase-reaction 
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MATERIALS AND METHODS 
 
 
The present study was conducted after getting the approval from the ethical  
 
committee of Stanley medical college. 
 
 
It’s an  age and sex matched comparative study. Eighty cases of  PTB were  
 
taken  for  the study of  which, forty  were  freshly  diagnosed,  sputum  for  
 
AFB +ve ( GroupI ) , and forty  were completely  treated for 6 months with   
 
ATT and had completely recovered (GroupII). 
 
 
Forty  healthy  subjects  without  any  history  of  PTB infection  were  also  
 
included in the study as controls. 
 
 
The  study subjects were  selected  from those attending the TB- Tambaram  
 
sanatorium  from  January, 09 to April, 09. The study  subjects were clearly  
 
informed  of  the  nature of  the study and the blood samples were collected  
 
after getting written informed consent. 
                
 
The  Control  subjects  were  volunteers  with  good  health as evidenced by  
 
medical history, complete physical examination and routine laboratory tests  
 
performed before the commencement of the study. 
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SAMPLE COLLECTION: 
 
 
5ml of venous blood drawn from the subjects. Individuals fasted for 12 hour  
 
prior to sample collection. After  collection, blood  samples were allowed to  
 
clot  and then  centrifuged to separate  serum. Serum samples were stored at  
 
4.c for 1 week. 
 
 
The  samples  were  analyzed for serum Ferroxidase, serum Albumin, serum  
 
total Protein, serum total Bilirubin, serum ALT, serum AST, serum Alkaline  
 
phosphatase, blood  Urea, serum  Creatinine  and  the  results were analyzed  
 
based on the data collected. 
 
 
INCLUSION CRITERIA 
 
 
1. PTB  patients  include  both  males  and  females  between  20  to   60yrs. 
 
 
2. PTB  patients  who  were  freshly  diagnosed  with  sputum  for  AFB+ve. 
 
 
3. PTB  patients  who  had  completed  their  treatment  and  had completely  
 
    recovered from the infection. 
 
 
4. Apparently  healthy  individuals  of  both  sexes  in  the  same  age group. 
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EXCLUSION CRITERIA 
 
 
1. PTB   patients  with  any  other  active  medical  conditions  like  Pleural  
 
   effusions  ( extra Pulmonary TB ) ,  HIV infection ,  Nephrotic syndrome, 
 
   Bronchial asthma etc. 
 
 
2. Children with Primary pulmonary TB. 
 
 
3. Pregnant PTB patients. 
 
 
4. PTB patients with hepatocellular damage. 
 
 
5. PTB patients with renal damage. 
 
 
6. PTB  patients  with  malignancies  such  as leukemia, lymphoma, breast  
 
   carcinoma. 
 
 
7. Patients  not  willing  to  give  written  informed  consent were excluded  
 
    from the study. 
 
 
QUANTITATIVE ESTIMATION OF SERUM FERROXIDASE58 
 
 
Serum Ferroxidase activity of Ceruloplasmin  was determined  by end point  
 
measurement method using ferrous ions. 
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PRINCIPLE: 
 
 
Serum was  incubated with  known   amount of  ferrous ion  in acetate  buffer.  
 
Ferroxidase activity  of Cp oxidizes  ferrous ions  to ferric ions. At the end of  
 
the incubation  period, chromogen was  added. It forms  a highly colored  Fe2+  
 
complex   with  non  oxidized  ferrous  ions,  blue   color  intensity  was  then  
 
measured   photo metrically  at  600nm . The   difference    in   the   Fe2+   ion  
 
concentration before and after the enzymatic reaction indicated the amount of  
 
oxidized Fe2+ions.The  amount of  enzyme that converted 1μmol of substrate  
 
into product per minute was defined as one unit. 
 
 
REAGENTS: 
 
 
Reagent1: Sodium acetate buffer, 0.45mol/l                        
 
 
36.91gm  of  sodium  acetate  was  dissolved  in  1000ml of  deionized water.  
 
25.87 ml  of  reagent  grade  glacial  acetic acid  was  diluted to 1000ml with  
 
deionized  water. 940ml  of sodium acetate solution was mixed with 60ml of  
 
acetic  acid  solution. pH  adjusted to 5.8. 1ml of  chloroform was added.The  
 
buffer  solution  is    stable  for    at  least  6  months   at   room   temperature. 
 
 
Reagent2: Substrate solution, 367μmol/l 
 
9.9gm of  thiourea   was dissolved in 1000 ml of deionized water  and  then  
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0.1440 gm  of   Fe  (NH4)2(SO4)2.6H2O  was  dissolved  in  1000ml  of  this  
 
130mmol/l   thiourea solution.1 ml of chloroform was added. The  substrate  
 
solution is stable for at least 6months at 4.c. 
 
 
Reagent3: Chromogen solution-18mmol/l 
 
 
0.8899gm of 3-(2-pyridyl)-5, 6-bis [2-(5-furyl sulfonic acid)]-1, 2, 4-triazine  
 
was dissolved in 100ml of buffer solution.The chromogen  solution  is stable  
 
for at least 6months at 4.c. 
 
 
CALIBRATION: 
 
 
The  calibrator  used  was  reagent  grade   deionized  water .  Six    different  
 
concentrations  of  Fe2+ions  were  prepared. They were 60μmol/l, 50 μmol/l,  
 
40 μmol/l, 30 μmol/l, 20 μmol/l, 10 μmol/l. 
 
         
The  absorbance of the calibrators is plotted against the concentration of Fe2+  
 
ions on a graph paper. 
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TABLE 
 
 
Blank Absorbance: 0.02 
 
 
Standard 
concentration(μmol/l) 
Corrected Absorbance(std-
Blank) 
60 1.20 
50 0.98 
40 0.85 
30 0.60 
20 0.41 
10 0.18 
 
 
 
PROCEDURE 
 
 
 Blank Standard Test 
Distilled water 78 μl 3 μl - 
Serum - - 3 μl 
Buffer 350 μl 350 μl 350 μl 
After 1min, substrate added 
Substrate - 75 μl 75 μl 
Incubated for 3.8min at 37.c, then added 
Chromogen 30 μl 30 μl 30 μl 
 
 
 
3μl  of  serum or calibrator  was  added  to 350 μl of reagent1.Then, 75 μl of  
 
reagent2 was added after 1min, and the mixture was incubated for 3.8min at  
 
37.c .At  the  end  of  incubation period, 30 μl of reagent3 was added and the  
 
absorbance of the colored complex at 600nm was recorded. 
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CALCULATION: 
 
     
Unknown Fe2+ (μmol/l) =  Test-Blank absorbance      x  concentration of std 
                                           Std-Blank absorbance 
         
 
Enzyme activity= (C1-C2) x t-1 x df     
                     
                          =∆Cs x t-1 x df   , where 
 
 
C1 is the substrate  concentration at the beginning of the enzymatic  reaction. 
 
C2  is  the  substrate   concentration  at  the  end  of   the  enzymatic  reaction. 
 
t  is the incubation time of the enzyme with the substrate. 
 
df  is   the  dilution  rate  of  the  sample  ( total volume / sample volume ) . 
  
 
Enzyme activity=∆Cs x (1/3.8) x (458/3) 
                                
                           =∆Cs x 40 U/L 
 
 
REFERENCE VALUE: Adult-500 to 1110 U/L 
 
 
 
QUANTITATIVE ESTIMATION OF SERUM ALBUMIN                       
 
(by Bromocresolgreen, dye binding method) 
 
 
 
PRINCIPLE : Albumin  in  a  buffered  solution  reacts with the anionic  
 
bromocresol  green, a   dye binding reaction  gives a proportionate green  
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color which was measured at 628nm (600-650nm). 
 
REAGENTS :( Bromocresol green) 
 
          
             Succinic acid-94 mmol/l 
           
             NaOH-10.2 mmol/l 
         
             BCG-0.149 mmol/l 
 
 
 
PROCEDURE: 
 
 
1ml  of reagent  was  added to 10 μl  of sample , incubated for 1min at  room  
 
temperature, mixed and read. 
 
 
System Parameters 
 
 
Reaction type End point 
Reaction slope Increasing 
Wavelength 628nm 
Flow cell temperature 30.c 
Incubation 1min at room temperature 
Sample volume 10 μl 
Reagent volume 1ml 
Standard concentration 5g/dl 
Zero setting with Reagent blank 
 
 
 
REFERENCE VALUE: Adult: 3.5 to 5 g/dl 
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QUANTITATIVE ESTIMATION OF SERUM TOTAL PROTEIN  
 
(by Biuret method.) 
 
 
PRINCIPLE: 
 
 
Proteins in serum react with biuret reagent to form a purple colored complex  
 
which is measured colorimetrically.The intensity of the color developed was  
 
directly proportional to the amount of proteins present in the sample. 
 
 
REAGENTS: 
 
 
1. Biuret diluent: 5gm KI in 0.25mol NaOH/L 
 
 
2. Stock Biuret reagent: 15gm of CuSO4.5H2O dissolved in 70 ml of water.  
 
Prepared  a solution of  45 gm  Rochelle salt  ( potassium  sodium  tartrate,  
 
tetrahydrate )  in  600 ml of  biuret diluent and then added CuSO4 solution.  
 
Biuret diluent is then added to 1000ml. 
     
 
3. Working Biuret: The stock biuret was diluted 5-fold with biuret  diluent. 
 
 
PROCEDURE: 
 
 
10  μl of serum was  added to 500 μl of reagent. Mixed well, incubated for  
 
10min at room temperature and read at 540nm. 
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REFERENCE VALUE: Adult: 6.4 to 8.3 g/dl 
 
 
QUANTITATIVE ESTIMATION OF SERUM TOTAL BILIRUBIN      
 
(by Jendrassik and Grof method) 
 
 
PRINCIPLE: 
 
 
Serum  was  added  to  a solution of  sodium acetate  and  caffeine-sodium  
 
benzoate. The  sodium acetate buffers the pH of the diazotization reaction,  
 
while  the  caffeine-sodium  benzoate accelerates the coupling of bilirubin  
 
with diazotized sulfanilic acid to form azobilirubin and the intensity of the  
 
color was read at 620nm. 
 
 
REAGENTS: 
 
 
1. Hydrochloric acid, 0.05mol/l 
 
 
2. Caffeine reagent (50g of caffeine, 75g of sodium benzoate and 125g  of  
 
    sodium acetate was added to 1L of distilled water. 
 
 
3. ReagentA (5g of sulfanilic acid added to 15ml of concentrated HCL and  
 
   diluted to 1L with distilled water). 
 
 
4. ReagentB (500mg of sodium nitrite was dissolved in100 ml of  distilled  
 
 
 
38
    water). 
 
 
5. Diazo reagent (10ml of reagent A+0.25ml of reagent B). 
 
 
6. Ascorbic acid solution (4g/100ml). 
 
 
7. Tartrate solution (100g of NaOH and 350g of sodium tartrate was added  
 
    to 1L of distilled water). 
 
 
 
PROCEDURE: 
        
  
500 μl caffeine benzoate + 125 μl of Diazo reagent + 50 μl of sample were  
 
added , incubated  for 10min  at  room temperature. Then 25 μl of ascorbic 
 
acid  solution , 375 μl  of  alkaline  tatrate  solution, 250 μl  of 0.05N HCL  
 
were added and read at 620nm. 
 
 
 
REFERENCE VALUE: Adult: 0 to 2.0 mg/dl. 
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QUANTITATIVE ESTIMATION OF SERUM AST                  
 
(Aspartate aminotransferase) by UV-Kinetic method 
 
 
PRINCIPLE: 
 
                                                   AST 
L-Aspartate+α Ketoglutarate                  Oxaloacetate+L-Glutamate 
 
                                                  MDH 
Oxaloacetate + NADH +  H+                               L-Malate    +   NAD+ 
 
AST-Aspartate amino transferase 
 
MDH-Malate dehydrogenase 
 
 
There was decrease in absorbance at 340nm as NADH got converted to  
 
NAD+.The rate of decrease in absorbance was measured. 
 
 
 
REAGENTS: 
 
 
MDH≥800U/L 
 
LDH≤4000U/L 
 
NADH>0.20mmol/l 
 
αKetoglutarate>13mmol/l 
 
Tris buffer, pH7,80-88mmol/l 
 
L-Aspartate-264mmol/l 
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PROCEDURE: 
 
 
1ml of reagent was added to 100 μl of sample at 37.c, mixed and read at  
 
340nm. 
  
 
REFERENCE VALUE: Adult :< 40 IU/L (37.c) 
 
 
QUANTITATIVE ESTIMATION OF SERUM ALT                     
 
(Alanine aminotransferase) by UV kinetic method 
 
 
PRINCIPLE: 
                                              
 
L-Alanine+2 oxoglutarate                     Pyruvate +L-Glutamate 
 
                                             LDH    
Pyruvate +   NADH  +  H+                    L-Lactate + NAD+             
 
 
ALT: Alanine aminotransferase 
 
LDH: Lactate dehydrogenase 
 
There was decrease in absorbance at 340nm as NADH got converted to  
 
NAD.The rate of decrease in absorbance was measured. 
 
 
REAGENTS: 
 
 
L-Alanine-500mmol/l 
 
NADH-0.18mmol/l 
ALT
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LDH≥1820IU/L 
 
2-oxoglutarate-12mmol/l 
 
Tris buffer, pH7.5 – 80mmol/l 
 
 
PROCEDURE: 
 
 
1ml  of  reagent was added to 100 μl of  sample at  37.c. Mixed  and  read  at  
 
340nm. 
 
 
REFERENCE VALUE: Females :< 31 IU/L at 37.c 
 
                                          Males :< 40 IU/L at 37.c 
 
 
QUANTITATIVE ESTIMATION OF SERUM  
 
ALKALINEPHOSPHATASE by PNPP (p-Nitrophenyl phosphate) method 
 
 
PRINCIPLE: 
 
 
Alkaline phosphatase hydrolyses PNPP into p-Nitrophenol and phosphate.At  
 
the  alkaline  pH  of  the  buffered  medium, p-Nitrophenol  was  yellow. The  
 
color developed by hydrolysis was measured at 405nm. 
 
 
REAGENTS: 
 
 
PNPP-10mmol/l 
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Diethanolamine-1mol/l 
 
Magnesium chloride-0.5mmol/l 
 
 
PROCEDURE: 
 
 
1ml  of  reagent  was  added  to 30 μl of sample at 37.c, mixed  and  read  at  
 
405nm. 
 
 
REFERENCE VALUE: Adult: 60 to 170 U/L (25.c) 
 
 
QUANTITATIVE ESTIMATION OF BLOOD UREA NITOGEN       
 
(by UV Kinetic Method) 
 
 
PRINCIPLE: 
        
 
Urea  was  hydrolyzed  in  the   presence  of  water  and  urease   to   produce  
 
ammonia  and  CO2. The ammonia  produced combines with α Ketoglutarate  
 
and  NADH in  the  presence of glutamate dehydrogenase to yield glutamate  
 
and NAD.The amount of urea nitrogen may be calculated by determining the  
 
absorbance  decrease  per minute relative to urea nitrogen standard at 340nm. 
 
 
REAGENTS: 
 
 
Tris buffer, pH7.55 – 75mmol/l 
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GLDH≥1000U/L 
 
Urease≥30,000 U/L 
 
NADH-0.32mmol/l 
 
αKetoglutarate-9mmol/l 
 
 
PROCEDURE: 
 
 
1ml  of  reagent  was  added  to  10 μl  of  sample  at 37.c, mixed and read at  
 
340nm. 
 
 
REFERENCE VALUE: BUN: 6-20 mg/dl 
 
 
 QUANTITATIVE ESTIMATION OF SERUM CREATININE                
 
(by modified Jaffe′s Method) 
 
 
PRINCIPLE: 
 
 
Creatinine present in the sample reacted with picric acid in alkaline medium  
 
and formed creatinine picrate (red colored complex) which was measured at  
 
490nm. 
 
 
REAGENTS: 
 
 
Saturated picric acid-10ml 
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0.75N NaOH-10ml 
 
Distilled water-20ml 
 
 
PROCEDURE: 
          
 
1ml of reagent was added to 100 μl of sample at 37.c, mixed and read at  
 
490nm. 
 
 
REFERENCE VALUE: Adult: 0.8 to 1.2 mg/dl. 
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RESULTS AND STATISTICAL ANALYSIS 
 
 
The  Present  study  was  conducted   on  the    subjects  attending  the  TB- 
 
Tambaram sanatorium  hospital. The total  number of subjects included for  
 
the  study  was 120. Out of 120,   40  were freshly diagnosed PTB cases, 40  
 
were completely treated cases and 40 were controls. 
 
 
Mean  and  Standard   deviation  of  variables - serum  Ferroxidase  , serum  
 
Albumin, serum F/A ratio, serum total Protein, serum total Bilirubin, serum  
 
AST ,  serum ALT ,  serum  Alkaline  phosphatase ,   Blood  Urea ,   serum  
 
Creatinine were  estimated for subjects in GroupI, GroupII and Controls (as  
 
shown in Table no.1). 
 
          
ANOVA  was  employed to find out the level of significance between three  
 
groups.  Student  independent  t  test  was  used  to find the P value between  
 
study  group  and  Control  [ as  shown  in table  no.7 ,8, 9 and 10( age  wise  
 
comparison) ,3,4,5 and 6 (sexwise comparison)].   
 
 
STATISTICAL RESULTS: 
 
 
1.Serum Ferroxidase level ranges between 550 – 1012 U/L in control, 820 –  
 
2102 U/L in GroupI, 719 – 1380 U/L in GroupII  ( estimated  by  end  point  
 
method using Ferrous ions). 
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2) Serum Albumin level ranges between 35 – 47g/l in control, 24 - 40 g/l  
 
in GroupI, 31 - 45 g/l in GroupII ( estimated  by  Bromocresol  green dye  
 
binding method). 
      
 
3) Serum F/A ratio level ranges  between 13 – 28.8 in control, 24.1 – 82.9  
 
in GroupI, 15.2 – 43.1 in GroupII. 
    
 
4) Serum  total  Protein  level ranges between 6.4 – 8.0g/dl in control, 7.4 –  
 
9.1 g/dl in GroupI, 6.6 – 8.2 g/dl in GroupII (estimated by Biuret method). 
 
 
5) Serum total Bilirubin level ranges between 0.2 -1.2mg/dl in control,0.3 –  
 
1.2 mg/dl  in  Group I, 0.2 – 1.1 mg/dl  in Group II(estimated by Jendrassik  
 
and grof method). 
 
 
6) Blood Urea level ranges between 15 – 37mg/dl in control , 15 - 39 mg/dl  
 
in  GroupI ,  16 - 38 mg / dl  in  GroupII (estimated by UV Kinetic method). 
 
    
7) Serum  Creatinine  level  ranges between 0.8 – 1.2 mg/dl in control, 0.7 –  
 
1.2  mg / dl  in Group I ,0.7 – 1.1 mg / dl  in GroupII (estimated by modified  
 
jaffe′s method). 
 
 
8) Serum AST level ranges between 13 – 40IU/L in control, 15 - 40 IU/L  
 
in Group I , 16 – 36  IU/L in Group II (estimated by UV Kinetic method). 
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9) Serum ALT level ranges between 11 – 40 IU/L in control, 10 - 38 IU/L  
 
in Group I, 10 – 40  IU/L in Group II  ( estimated by UV Kinetic method). 
   
 
10)Serum  Alkaline phosphatase ranges  between 60 – 125 U/L in control,  
 
51 - 132  U / L  in  Group I , 66 - 143  U / L  in Group II  ( estimated by p- 
 
Nitrophenyl phosphate method). 
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DISCUSSION 
 
 
Pulmonary  tuberculosis  is  a  global  disease  affecting  about  1 /3rd  of  the  
 
world’s  population  with its attendant  mortality and morbidity. PTB can  be  
 
diagnosed by a thorough evaluation of history, clinical symptoms and  signs,  
 
bacteriological and radiological features. But still, in quite a number of cases  
 
it  becomes  difficult  to  predict  the  activity  of  a  tubercular  lesion  where  
 
precise  information is not  available particularly in developing countries like  
 
India. 
 
  
LIMITATIONS OF EXISTING DIAGNOSTIC INVESTIGATIONS 
 
 
1. The  diagnosis  of  PTB   is  based primarily on the rapid and inexpensive,  
 
microscopic  examination  of  sputum  for  AFB  but  it is limited by its poor  
 
sensitivity (40-60%) 59. 
 
 
2. Mycobacterium  culture  is   able  to  detect  as  few  as  10  organisms per  
 
milliliter of sputum and  overcomes many of  the limitations of AFB staining    
 
but even with the use of broth-based culture systems,confirming the presence  
 
of MTB from the time of specimen collection takes at least a week59. 
  
 
3. Current  rapid  nucleic  acid  amplification  techniques  with  sensitivity of  
 
about  96 %  and  specificity  of  100 %  for AFB smear positive samples are  
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commercially  available.  But  their  performance  in  AFB  smear - negative  
 
specimens  is  less  impressive  with  sensitivities ranging from 48% to 53%.  
 
Moreover the accuracy of this testing may be reduced by the concurrent  use  
 
of ATT and inhibitors in the patient’s sputum which may give false- negative  
 
result59, 60. 
 
                
With  these  factors  taken  into account, the present study was undertaken to  
 
evaluate a new biochemical parameter for diagnosis of active  PTB infection  
 
and prognosis of PTB patients under treatment. In the present study, the PTB  
 
cases  were  compared  with apparently healthy controls.Also, the nutritional  
 
status  of the  PTB cases  and  control were assessed by estimating the serum  
 
Albumin  and  total  Protein  level .  Liver  function  was also analyzed in the  
 
PTB  cases and control using the enzymes- AST, ALT, Alkaline phosphatase.  
 
Renal  parameters - Urea  and  Creatinine  was  also analyzed in these groups. 
  
   
In the present study, age wise comparison of GroupI, GroupII with  controls  
 
was  made  (as shown in table no.7,8,9,and 10) . Based  on the age,  subjects  
 
were  divided into two age  groups - upto 40yrs and above 40yrs . Following  
 
results obtained: 
 
 
1. In  both  age  groups  there  was significant P value on comparison of the  
 
mean levels of serum Ferrroxidase (P=0.001), serum  Albumin  (P=0.001) and  
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serum F/A ratio (P=0.001) between GroupI and Control.    
  
 
2.In both age groups there was significant P value on comparison of  the  
 
mean levels of serum Ferrroxidase (P=0.001), serum Albumin  (P=0.001)  
 
and serum F/A ratio (P=0.001) between GroupII and Control. 
  
 
In  the  present study,  equal number of Male and Female  subjects   were  
 
selected  in Group I , Group II  and controls to make sexwise comparison. 
 
(as shown in table no.3,4,5 and 6). Following results obtained: 
 
  
1.In both males and females, there was significant P value on comparison  
 
of  the  mean   levels  of  serum Ferrroxidase (P=0.001 ) , serum Albumin  
 
(P=0.001) and  serum  F/A  ratio ( P=0.001 ) between GroupI and Control. 
 
 
2.In both males and females, there was significant P value on comparison 
 
of  the  mean  levels  of  serum  Ferrroxidase  ( P=0.001), serum Albumin  
 
(P=0.001) and serum  F/A  ratio  (P=0.001) between GroupII and Control. 
 
  
In the present study, the mean levels of serum Ferroxidse, serum Albumin,  
 
serum  F/A  ratio ,  serum  total Protein, serum total Bilirubin, serum AST,  
 
serum ALT , serum  Alkaline  phosphatase, Blood Urea, serum Creatinine  
 
was found to be normal in the control subjects. 
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In  the  present  study ,  Group I i.e.,  freshly diagnosed sputum for AFB+ve  
 
subjects showed significant increase in the mean level of serum Ferroxidase  
 
as  compared  to  controls .  These  findings  suggest   that  levels  of  serum  
 
Ferroxidase  are  related  with  the  activity  of  tubercular  process61 . Serum  
 
Ferroxidase , an acute phase reactant got increased due to tissue destruction,  
 
increase in severity of the lesion and  persistence of fever62. 
 
 
The  present study in Group I showed significant decrease in the mean level  
 
of  serum  albumin  as compared to controls. Albumin being  an acute phase  
 
reactant,  its  level  in the serum decrease  with increase in severity63.This is  
 
because of two reasons. 
  
 
1.  Hemodynamic  changes  that   occur   in   response   to   T   cell  reaction. 
      
2.  Decreased   synthesis  as   a   result  of   direct   inhibition   by  cytokines.        
       
 
Decrease  in  the  Albumin  level supports the induction of malnutrition and  
 
loss of weight by MTB infection63. 
 
 
In the present  study, the  mean level of total serum Protein was increased in  
 
GroupI as compared to controls. This has been solely due  to  increase in the  
 
globulin  fractions  as  the  albumin  fraction  has  been  decreased  in   these  
 
patients. Serum ferroxidase is one of the globulin fraction that contributes to  
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the increase in total Protein level64. 
  
 
Regarding  Albumin-Globulin ratio, the ratio  decreases  in direct proportion  
 
to the severity of the lesion65. 
 
 
In the present study, GroupI showed significant elevation of serum F/A ratio  
 
as compared to  controls. Serum  F/A  ratio  is statistically easier to compare  
 
the  PTB  patients  with  the controls  rather  than  the  individual parameters. 
  
  
In the present study, GroupII patients showed that the mean  levels of serum  
 
Ferroxidase  decreased    considerably   after   6  months    of  chemotherapy  
 
compared  to  Group I . The  fall of  serum  Ferroxidase  might be due to the  
 
caseation  or  diminution  in  tissue  destruction , healing  of  the lesions and  
 
subsidence of fever as a result of ATT. 
  
  
The  present  study   showed  that  the  mean  level  of  serum   Albumin was  
 
increased  to near  normal in completely treated Group II  cases compared to  
 
freshly  diagnosed PTB patient i.e., GroupI.The elevation of serum Albumin  
 
level   in    completely    treated   cases   suggest    the   cessation   of    acute  
 
hemodynamic  changes  that occurred  previously  in PTB freshly diagnosed  
 
cases in response to tissue damage.  
  
 
Also  study  on  Group II  showed  that  the mean level of serum total Protein  
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was  decreased  to  near  normal  as  compared  to  Group I . It  might  be due  
 
to increased synthesis of Albumin and reduction in globulin level (i.e.,serum  
 
ferroxidase-α2 globulin) 66. 
  
 
In  Group II   treated  cases ,  the  mean  F/A  ratio  was  found   significantly  
 
reverting back near to the control levels after complete treatment for 6months.  
 
These  findings  substantiates  the  relationship  of  serum  F/A ratio with  the  
 
activity of the tubercular lesion. 
  
  
In  the  present  study , there was no significant change in  the mean levels  of  
 
other  parameters in Group I and GroupII as compared to controls  suggesting  
 
that  liver  function  are  not  entirely  affected  and  renal function  is  normal. 
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SUMMARY AND CONCLUSION 
 
 
Pulmonary  Tuberculosis  is  a  communicable  disease of global importance.  
 
The present study on PTB patients (both freshly diagnosed and treated cases)  
 
showed that there was highly significant increase in the serum Ferroxidase /  
 
Albumin ratio level in freshly diagnosed PTB cases which on ATT treatment  
 
falls  back  to  near  normal  level  on  comparison  with  apparently  healthy  
 
individuals.  
 
           
The serum F/A ratio level is useful in predicting the course of PTB infection.  
 
It shows the degree of tuberculosis activity and thus it may serve  as  a guide  
 
in the management of PTB disease. 
                   
  
A  favorable  course  will  always  be associated with a tendency towards the  
 
near  normalization  of serum  F / A  ratio  and  the  patient is not considered  
 
healed unless the serum F/A ratio is near normal. 
  
                  
The   method   employed   to   estimate   serum  Ferroxidase   (  by  end point  
 
measurement   method   using   ferrous   ions  )   and   serum  Albumin   (  by  
 
Bromocresolgreen  dye  binding  method )  level  are  simple, rapid and cost- 
 
effective .  Hence   serum  F / A   ratio  can  feasibly  be   incorporated   as  a  
 
biochemical marker to assist in diagnosis and prognosis of PTB. 
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SCOPE FOR FURTHER STUDY 
 
 
Studies can be conducted to assess the levels of serum Ferroxidase /Albumin  
 
ratio in 
 
 
1. TB Patients with HIV infection. 
 
2. Children with primary pulmonary tuberculosis. 
 
3. Extra pulmonary TB patients. 
 
4. MDR-TB patients. 
 
5. Other Mycobacterium infection. 
 





PROFORMA 
 
 
Stanley Medical College Hospital                                      Date : 
Chennai. 
 
Name:                                                                                    OP/IP No: 
 
Age: 
 
Sex: 
 
Occupation: 
 
Clinical History: 
 
On Examination                                                 
 
Height:                                   Blood Pressure:                      Heart rate: 
 
Weight:                                  Respiratory rate:                                                                           
 
Cardiovascular system:         Central nervous system: 
 
Respiratory system:               Abdomen: 
                                           
Investigations: 
 
1.  Serum Ferroxidase:                                   6. Serum Creatinine: 
 
2.  Serum Albumin:                                        7. Serum AST: 
 
3.  Serum Ferroxidase/Albumin ratio:            8. Serum ALT: 
 
4.  Serum Total Protein:                                 9. Serum Alkaline Phosphatase    
 
5.  Serum Total Bilirubin:                             10.Blood Urea:  
 
 
 
TABLE NO.1 
MEAN VALUES OF  VARIABLES  IN  GROUPS 
S.No Variables Group N Mean±SD 
1 Ferroxidase 
Group I 40 1616.02±216 
Group II 40 980.22±189 
Controls 40 800.87±130 
Total 120 1132.37±395 
2 Albumin 
Group I 40 32.20±3 
Group II 40 38.87±4 
Controls 40 45.17±3.2 
Total 120 40.08±4.84 
3 F/A Ratio 
Group I 40 50.06±10 
Group II 40 26.07±7 
Controls 40 20.21±4 
Total 120 32.11±15.2 
4 T.Protein 
Group I 40 8.72±0.38 
Group II 40 7.70±0.35 
Controls 40 7.50±0.46 
Total 120 7.97±0.66 
5 T.Bilirubin 
Group I 40 0.83±0.2 
Group II 40 0.71±0.3 
Controls 40 0.79±0.2 
Total 120 0.78±0.2 
6 SGOT 
Group I 40 21.9±6.1 
Group II 40 23.6±6.0 
Controls 40 20.9±6.5 
Total 120 23.1±6.2 
7 SGPT 
Group I 40 26.3±7.5 
Group II 40 26.6±7.3 
Controls 40 27.1±7.8 
Total 120 26.7±7.5 
8 Alk.phosp 
Group I 40 92.2±22.9 
Group II 40 85.72±22.2 
Controls 40 89.7±21.3 
Total 120 92.9±22.0 
9 Urea 
Group I 40 19.2±5.5 
Group II 40 20.5±6.1 
Controls 40 19.9±7.0 
Total 120 24.6±6.2 
10 Creatinine 
Group I 40 1.1±1.1 
Group II 40 0.9±0.1 
Controls 40 0.8±0.1 
Total 120 1.0±0.6 
 
TABLE NO.2 
 
ANOVA 
 
COMPARISON BETWEEN AND WITHIN GROUPS 
S.No Variables Groups Mean square f Significance 
1 Ferroxidase 
Between 
groups 7339183.9 
220.1 0.001 Within groups 33337.9 
Total   
2 Albumin 
Between 
groups 570.308 
40.4 0.001 Within groups 14.107 
Total   
3 F/A Ratio 
Between 
groups 10002.2 
153 0.001 Within groups 65.33 
Total   
4 T.Protein 
Between 
groups 17.2 
105.9 0.001 Within groups 0.16 
Total   
5 T.Bilirubin 
Between 
groups 0.146 
2.277 0.107 Within groups 0.064 
Total   
6 SGOT 
Between 
groups 45.033 
1.154 0.319 Within groups 39.01 
Total   
7 SGPT 
Between 
groups 6.35 
0.111 0.895 Within groups 57.53 
Total   
8 Alk.phosp 
Between 
groups 21.22 
0.043 0.958 Within groups 493.2 
Total   
9 Urea 
Between 
groups 12.4 
0.314 0.731 Within groups 39.4 
Total   
10 Creatinine 
Between 
groups 0.51 
1.168 0.315 Within groups 0.44 
Total   
 
 
 
 
 
 
 
 
TABLE NO.3 
 
SEXWISE COMPARISON BETWEEN GROUP I AND CONTROLS 
 
(MALE) 
 
 
S.No Variable Group I Control P ValueMean±SD Mean±SD 
1 Ferroxidase 1605.70±209.06 793.47±132.13 0.001
2 Albumin 32.65±4.29 41.28±3.22 0.001
3 F/A Ratio 50.260±11.81 19.97±4.71 0.001
              
                 P<0.05=significant 
 
 
 
 
 
 
TABLE NO.4 
 
SEXWISE COMPARISON BETWEEN GROUP II AND CONTROLS 
 
(MALE) 
 
 
S.No Variable Group II Control P ValueMean±SD Mean±SD 
1 Ferroxidase 992.05±197.18 793.47±132.13 0.001
2 Albumin 40.75±3.52 43.28±3.22 0.001  
3 F/A Ratio 26.38±7.52 19.97±4.71 0.001
                 
                  P<0.05=significant 
 
 
 
 
 
 
TABLE NO.5 
 
SEXWISE COMPARISON BETWEEN GROUP I AND CONTROLS 
 
(FEMALE) 
 
 
S.No Variable Group I Control P ValueMean±SD Mean±SD 
1 Ferroxidase 1626.35±228.73 809.05±131.87 0.001
2 Albumin 33.10±4.01 43.05±3.29 0.001
3 F/A Ratio 49.86±9.9 20.48±4.7 0.001
                 
                P<0.05=significant 
 
 
 
 
 
 
 
 
TABLE NO.6 
 
SEXWISE COMPARISON BETWEEN GROUP II AND CONTROLS 
 
(FEMALE) 
 
 
S.No Variable Group II Control P ValueMean±SD Mean±SD 
1 Ferroxidase 968.40±186.77 809.05±131.87 0.001
2 Albumin 38.65±4.25 43.05±3.29 0.001
3 F/A Ratio 25.77±7.8 20.48±4.7 0.001
             
                P<0.05=significant 
 
 
 
 
TABLE NO.7 
 
AGEWISE COMPARISON BETWEEN GROUP I AND CONTROLS 
(upto 40 ) 
 
 
S.No Variable Group I Control P ValueMean±SD Mean±SD 
1 Ferroxidase 1548.87±225.32 797.22±147.45 0.001
2 Albumin 32.83±3.49 43.22±3.05 0.001
3 F/A Ratio 47.64±8.81 20.11±5.07 0.001
          
           P<0.05=significant 
 
 
 
 
 
 
 
 
TABLE NO.8 
 
 
AGEWISE COMPARISON BETWEEN GROUP II AND CONTROLS 
(upto 40 ) 
 
 
S.No Variable Group II Control P ValueMean±SD Mean±SD 
1 Ferroxidase 986.04±210.44 797.22±147.45 0.001
2 Albumin 38.81±3.97 43.22±3.05 0.001
3 F/A Ratio 26.40±8.44 20.11±5.07 0.001
           
           P<0.05=significant 
 
 
 
 
TABLE NO.9 
 
AGEWISE COMPARISON BETWEEN GROUP I AND CONTROLS 
(above 40) 
 
 
S.No Variable Group I Control P ValueMean±SD Mean±SD 
1 Ferroxidase 1716.75±161.34 803.86±118.43 0.001
2 Albumin 32.93±5.01 42.13±3.41 0.001
3 F/A Ratio 53.69±12.66 20.30±4.4 0.001
                  
                   P<0.05=significant 
 
 
 
 
 
 
 
 
TABLE NO.10 
 
AGEWISE COMPARISON BETWEEN GROUP II AND CONTROLS 
(above 40) 
 
 
S.No Variable Group II Control P ValueMean±SD Mean±SD 
1 Ferroxidase 973.11±167.24 803.86±118.43 0.001
2 Albumin 39.66±3.83 42.13±3.41 0.001
3 F/A Ratio 25.68±6.62 20.30±4.4 0.001
                   
                   P<0.05=significant 
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